MediLink Therapeutics has entered into a new collaboration and exclusive licensing agreement with Roche for the development and commercialization of YL201, an investigational novel antibody-drug conjugate (ADC) asset targeting B7H3 across numerous solid tumor types.
Under the agreement, MediLink will grant Roche an exclusive license to develop, manufacture and commercialize YL201 worldwide, excluding the mainland of China, the Hong Kong Special Administrative Region and the Macau Special Administrative Region. MediLink will receive upfront and near-term milestone payments of $570 million, together with additional development, regulatory and commercial milestone payments and tiered royalties on net sales of YL201 in the licensed territory.
MediLink Therapeutics is a clinical-stage biotech company dedicated to developing innovative conjugated drugs for global patients, with headquarters in Suzhou, China and R&D centers in Shanghai, Boston and Singapore. It received Breakthrough Therapy Designation from the FDA for YL201 for the treatment of small cell lung cancer in June 2025, following the FDA’s prior conferral of three Orphan Drug Designations for the ADC.
The S&C team advising MediLink included Nader Mousavi, Rachel Yu, Elizabeth Cheung and Jack Baum. Davis Wang and Stephen Profeta advised on tax matters. Ryan Logan advised on data privacy matters, and Kyle Mach advised on antitrust matters. Matt Hurd and Brad King provided valuable advice.